Omeprazole

Generic Name: Omeprazole

Brand Names: Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₉N_₃O_₃S

CAS Number: 73590-58-6

Unique Ingredient Identifier: KG60484QX9

Background: Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs . Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults .

Indication: Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:

• Treatment of active duodenal ulcer in adults

• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer

recurrence in adults

• Treatment of active benign gastric ulcer in adults

• Reduction of risk of upper gastrointestinal (GI) bleeding in critically ill adult patients.

• Treatment of symptomatic gastroesophageal reflux disease (GERD) in

patients 1 year of age and older

• Treatment of erosive esophagitis (EE) due to acid-mediated GERD in

patients 1 month of age and older

• Maintenance of healing of EE due to acid-mediated GERD in patients 1

year of age and older

• Pathologic hypersecretory conditions in adults

Associated Conditions: Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas

Clinical Trials

A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: zongertinib
Drug: midazolam
Drug: omeprazole
Drug: repaglinide

First Posted Date: 2024-07-10

Last Posted Date: 2024-11-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT06494761

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Reducing Gastrointestinal Bleeding With Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism

Phase 3

Not yet recruiting

Conditions: Venous Thromboembolism
Gastro Intestinal Bleeding
Blood Clot

Interventions: Drug: Omeprazole 20 mg Oral Tablet
Other: Placebo

First Posted Date: 2024-05-01

Last Posted Date: 2024-05-01

Lead Sponsor: Deborah Siegal

Target Recruit Count: 360

Registration Number: NCT06393868

A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.

Phase 1

Not yet recruiting

Conditions: Hodgkin Lymphoma
Non Hodgkin Lymphoma

First Posted Date: 2024-04-25

Last Posted Date: 2024-08-28

Lead Sponsor: Murdoch Childrens Research Institute

Target Recruit Count: 10

Registration Number: NCT06383338

Locations: 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy

Early Phase 1

Recruiting

Conditions: Colorectal Neoplasia

Interventions: Drug: Omeprazole
Drug: Aspirin

First Posted Date: 2024-04-22

Last Posted Date: 2025-04-10

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 24

Registration Number: NCT06378398

Locations: 🇺🇸
The University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States